

Attorney's Docket No. 5470-148

#9/A
DLunkert
PATENT 5/1/99

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Baldwin et al.

Serial No.: 08/959,160

Filed: 28 October 1997

For: Use of NF- κ B Inhibition in
Combination Therapy for Cancer



Examiner: T. McKelvey

Group Art Unit: 1636

9 April 1999

Assistant Commissioner for Patents
Washington, DC 20231

RESPONSE AND AMENDMENT

Sir:

The following is in response to the non-final Office Action dated 22
December 1998.

In the Claims

Please amend the claims as follows:

B1
A 1. (amended) A method of enhancing the cytotoxic effects of an antineoplastic
chemotherapeutic agent, comprising administering to a subject in need of such therapy a
therapeutically effective amount of an NF- κ B inhibitor in conjunction with the administration
of the chemotherapeutic agent, whereby the cytotoxic effect of said chemotherapeutic agent
is increased compared to that which would occur in the absence of said NF- κ B inhibitor.

B2
A 2 6. (amended) A method of enhancing chemotherapeutic cytotoxicity in a subject treated
with an antineoplastic chemotherapeutic agent, comprising administering to the subject a
therapeutically effective amount of an NF- κ B inhibitor in conjunction with the administration
of the chemotherapeutic agent, whereby the cytotoxic effect of said chemotherapeutic agent
is increased compared to that which would occur in the absence of said NF- κ B inhibitor.